NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Financial Conflicts of      Interest Policy   Contact the NSABP   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-51   Protocol B-52   Protocol B-53/S1207   Protocol B-55/BIG 6-13 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

Annotated Bibliography of NSABP Publications Two Months of Doxorubicin-Cyclophosphamide With and Without Interval Reinduction Therapy Compared with Six Months of Cyclophosphamide, Methotrexate, and Fluorouracil in Positive-Node Breast Cancer Patients with Tamoxifen-Nonresponsive Tumors: Results from NSABP B-15 Fisher B, Brown AM, Dimotrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, and Deutsch M Journal of Clinical Oncology 8:1483-1496, 1990 Abstract The National Surgical Adjuvant Breast and Bowel Project (NSABP) implemented protocol B-15 to compare 2 months of Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and cyclophosphamide (AC) with 6 months of conventional cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with breast cancer nonresponsive to tamoxifen (TAM, T). A second aim was to determine whether AC followed in 6 months by intravenous (IV) CMF was more effective than AC without reinduction therapy. Through 3 years of follow-up, findings from 2,194 patients indicate no significant difference in disease-free survival (DFS, P = .5), distant disease-free survival (DDFS, P = .5) or survival (S, P = .8) among the three groups. Since the outcome from AC and CMF was almost identical, the issue arises concerning which regimen is more appropriate for the treatment of breast cancer patients. AC seems preferable since, following total mastectomy, AC was completed on day 63 versus day 154 for conventional CMF; patients visited health professionals three times as often for conventional CMF as for AC; women on AC received therapy on each of 4 days versus on each of 84 days for conventional CMF; and nausea-control medication was given for about 84 days to conventional CMF patients versus for about 12 days to patients on AC. The difference in the amount of alopecia between the two treatment groups was less than anticipated. While alopecia was almost universally observed following AC therapy, 71% of the CMF patients also had hair loss and, in 41%, the loss was greater than 50%. This study and NSABP B-16, which evaluates the worth of AC therapy in TAM-responsive patients, indicate the merit of 2 months of AC therapy for all positive-node breast cancer patients. National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.